[go: up one dir, main page]

MX2023004969A - Metodos para tratar y prevenir infeccion por c. difficile. - Google Patents

Metodos para tratar y prevenir infeccion por c. difficile.

Info

Publication number
MX2023004969A
MX2023004969A MX2023004969A MX2023004969A MX2023004969A MX 2023004969 A MX2023004969 A MX 2023004969A MX 2023004969 A MX2023004969 A MX 2023004969A MX 2023004969 A MX2023004969 A MX 2023004969A MX 2023004969 A MX2023004969 A MX 2023004969A
Authority
MX
Mexico
Prior art keywords
difficile
infection
treating
preventing
methods
Prior art date
Application number
MX2023004969A
Other languages
English (en)
Inventor
Michael P Draper
S Ken Tanaka
Original Assignee
Paratek Pharm Innc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paratek Pharm Innc filed Critical Paratek Pharm Innc
Publication of MX2023004969A publication Critical patent/MX2023004969A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen métodos para tratar o prevenir infección causada por C. difficile y las afecciones patológicas asociadas, relacionadas con infección por C. difficile.
MX2023004969A 2016-03-24 2018-09-20 Metodos para tratar y prevenir infeccion por c. difficile. MX2023004969A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662312996P 2016-03-24 2016-03-24
US201662320053P 2016-04-08 2016-04-08

Publications (1)

Publication Number Publication Date
MX2023004969A true MX2023004969A (es) 2023-05-24

Family

ID=59900751

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018011413A MX2018011413A (es) 2016-03-24 2017-03-24 Metodos para tratar y prevenir infeccion por c. difficile.
MX2023004969A MX2023004969A (es) 2016-03-24 2018-09-20 Metodos para tratar y prevenir infeccion por c. difficile.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018011413A MX2018011413A (es) 2016-03-24 2017-03-24 Metodos para tratar y prevenir infeccion por c. difficile.

Country Status (13)

Country Link
US (3) US20170319603A1 (es)
EP (1) EP3432891A4 (es)
JP (3) JP7458706B2 (es)
CN (2) CN109152789A (es)
AU (3) AU2017238644B2 (es)
BR (2) BR112018069303A2 (es)
CA (1) CA3018872A1 (es)
MX (2) MX2018011413A (es)
MY (1) MY197627A (es)
PH (1) PH12018502020A1 (es)
RU (1) RU2751509C1 (es)
SG (2) SG10201913559VA (es)
WO (1) WO2017165729A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170319603A1 (en) * 2016-03-24 2017-11-09 Paratek Pharmaceuticals, Inc. Methods for treating and preventing c. difficile infection
TW202206081A (zh) * 2016-08-03 2022-02-16 美商派瑞泰Ｓｐｖ２有限公司 ９—胺甲基米諾四環素化合物及其用途
BR112019008897A2 (pt) * 2016-11-01 2019-08-13 Paratek Pharm Innc método para tratar pneumonia bacteriana adquirida na comunidade.
JP7110563B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110562B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP7110560B2 (ja) * 2017-09-06 2022-08-02 株式会社三洋物産 遊技機
JP2019136431A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136429A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
JP2019136430A (ja) * 2018-02-15 2019-08-22 株式会社三洋物産 遊技機
CA3111447A1 (en) * 2018-09-04 2020-03-12 Paratek Pharmaceuticals, Inc. Methods of treating mycobacterial infections using tetracycline compounds
KR102837762B1 (ko) * 2018-10-10 2025-07-23 누트리 컴퍼니 리미티드 클로스트리디움 디피실균 감염증의 예방 및/또는 치료제
WO2021252876A1 (en) * 2020-06-11 2021-12-16 Paratek Pharmaceuticals, Inc. Crystalline forms of omadacycline, methods of synthesis thereof and methods of use thereof
PT117254B (pt) 2021-05-26 2024-04-18 Hovione Farm S A Método de síntese de compostos 9-aminometil tetraciclinas
JP2023105293A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機
JP2023105292A (ja) * 2022-07-21 2023-07-28 株式会社三洋物産 遊技機

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113614A1 (en) * 1991-07-24 1993-02-04 Scott Donald Whalen Antimicrobial treatment methods and compositions
BRPI0112269B8 (pt) * 2000-07-07 2021-05-25 Paratek Pharm Innc composto de minociclina 9-aminometila substituída, e, composição farmacêutica
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
EP2332546A1 (en) * 2001-07-13 2011-06-15 Paratek Pharmaceuticals, Inc. Tetracyclines for the treatment of stroke
CN101340917A (zh) * 2005-12-22 2009-01-07 惠氏公司 用替加环素治疗胃肠道感染的方法
WO2007087416A2 (en) * 2006-01-24 2007-08-02 Paratek Pharaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
TW202332671A (zh) * 2008-05-19 2023-08-16 美商Ｐｒｔｋ Ｓｐｖ２公司 四環素化合物之甲苯磺酸鹽及同素異形體
US20110294726A1 (en) * 2009-02-11 2011-12-01 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
CA2795953C (en) * 2010-04-15 2021-09-14 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of clostridium difficile-associated infection and disease
WO2012050826A1 (en) * 2010-09-29 2012-04-19 St. Jude Children's Research Hostpital Methods for treating clostridium difficile infections
WO2012065028A2 (en) * 2010-11-11 2012-05-18 Concert Pharmaceuticals Inc. Substituted tetracyclines
JP6479685B2 (ja) * 2013-02-04 2019-03-06 セレス セラピューティクス インコーポレイテッド 病原性細菌生育の抑制のための組成物および方法
US20140274800A1 (en) * 2013-03-13 2014-09-18 Procarta Biosystems Ltd. Transcription factor decoys for the treatment and prevention of infections caused by bacteria including clostridium difficile
US20170319603A1 (en) * 2016-03-24 2017-11-09 Paratek Pharmaceuticals, Inc. Methods for treating and preventing c. difficile infection

Also Published As

Publication number Publication date
JP2022115985A (ja) 2022-08-09
AU2017238644B2 (en) 2022-12-15
US20250049819A1 (en) 2025-02-13
PH12018502020A1 (en) 2019-07-15
SG11201808246SA (en) 2018-10-30
AU2023200798A1 (en) 2023-03-09
CA3018872A1 (en) 2017-09-28
EP3432891A4 (en) 2019-10-30
AU2017238644A1 (en) 2018-10-25
MY197627A (en) 2023-06-29
JP2024023187A (ja) 2024-02-21
CN119454720A (zh) 2025-02-18
RU2751509C1 (ru) 2021-07-14
WO2017165729A1 (en) 2017-09-28
SG10201913559VA (en) 2020-02-27
CN109152789A (zh) 2019-01-04
JP7458706B2 (ja) 2024-04-01
BR112018069303A2 (pt) 2019-01-22
MX2018011413A (es) 2019-01-10
US20200281948A1 (en) 2020-09-10
EP3432891A1 (en) 2019-01-30
US20170319603A1 (en) 2017-11-09
BR122024000249A2 (pt) 2024-02-27
AU2025202020A1 (en) 2025-04-10
JP2019509318A (ja) 2019-04-04

Similar Documents

Publication Publication Date Title
MX2023004969A (es) Metodos para tratar y prevenir infeccion por c. difficile.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12018501378A1 (en) Compositions and methods for the treatment of hemoglobinopathies
PH12019501812A1 (en) Compositions and methods for the treatment of hemoglobinopathies
AU2019268074A1 (en) Methods for treating hepcidin-mediated disorders
MX2025006476A (es) Composiciones y metodos para oncologia inmunologica
PH12016502564A1 (en) Substituted nucleosides, nucleosides and analogs thereof
MA40404A (fr) Polythérapie pour traiter un paramyxovirus
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
MX2018003472A (es) Moduladores de la expresion de kras.
MY184870A (en) Immunomodulators
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2017008184A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
GB2541571A (en) Pharmaceutical compositions
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
NZ732756A (en) Processes for the preparation of a diarylthiohydantoin compound
WO2017096303A3 (en) Cerdulatinib for treating hematological cancers
PH12017500602A1 (en) Methods for treating ocular conditions
MX2019000246A (es) Formas en estado solido del dimesilato de palbociclib.
IL252197A0 (en) A method for treating, preventing or reducing the risk of skin infection
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
SG10201908248PA (en) Processes for preparing fluoroketolides
HK1255221A1 (zh) 使用卡多曲组合物进行治疗的方法